Synergistic Combinations of Tissue Kallikrein 1 with AI, IoT, and Blockchain Technologies for Enhanced Ischemic Condition Treatment
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates tissue kallikrein 1 dosage forms with cutting-edge technologies like AI, IoT, and blockchain to create a powerful system for treating ischemic conditions, offering enhanced efficacy, personalized treatment, and secure data management.
Background and Problem Solved
The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions. However, these forms had limitations in terms of efficacy, patient monitoring, and data security. The present inventive concept addresses these limitations by incorporating AI, IoT, and blockchain technologies to create a more comprehensive and effective treatment system.
Detailed Description of the Inventive Concept
The synergistic combinations disclosed herein comprise tissue kallikrein 1 dosage forms integrated with AI-powered monitoring modules, IoT-enabled sensors, and blockchain-based data storage units. These components work together to provide real-time monitoring of patient responses, personalized treatment plans, and secure recording of treatment outcomes. The AI-powered monitoring module analyzes patient data and generates customized treatment plans. The IoT-enabled sensor tracks dosage efficacy and provides real-time feedback. The blockchain-based data storage unit ensures secure and tamper-proof recording of treatment outcomes.
Novelty and Inventive Step
The integration of tissue kallikrein 1 dosage forms with AI, IoT, and blockchain technologies is new and non-obvious compared to the original patent. The synergistic combinations disclosed herein provide a unique and effective solution for treating ischemic conditions, overcoming the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of different AI algorithms, IoT-enabled devices, or blockchain-based platforms. Variations may also include the integration of additional technologies, such as machine learning or cloud-based data analytics, to further enhance the system's capabilities.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of ischemic conditions. The system's enhanced efficacy, personalized treatment, and secure data management capabilities make it an attractive solution for patients, healthcare providers, and pharmaceutical companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/4853 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K45/06 |
| C | C12 | C12Y304/21035 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically drug delivery systems and treatment methods for ischemic conditions, involving protein therapeutics and advanced medical technologies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or pharmaceutical scientist with expertise in protein formulation, medical device integration, data analytics, and personalized medicine technologies, holding advanced degrees and practical experience in translating biological discoveries into clinical applications
Obviousness Rationale
A person having ordinary skill in the art would recognize that integrating advanced monitoring and data management technologies with existing tissue kallikrein 1 dosage forms represents a predictable extension of known medical technology trends. The combination of AI, IoT, and blockchain with established pharmaceutical delivery methods follows standard technological convergence patterns in personalized medicine. A PHOSITA would understand that enhancing drug delivery with real-time monitoring and secure data management is a logical progression in treatment optimization strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,608 |
|---|---|
| Title | Dosage forms of tissue kallikrein 1 |
| Assignee(s) | DiaMedica Inc. |